[go: up one dir, main page]

PE20150635A1 - Profarmacos de aminoquinazolina inhibidora de cinasa - Google Patents

Profarmacos de aminoquinazolina inhibidora de cinasa

Info

Publication number
PE20150635A1
PE20150635A1 PE2015000277A PE2015000277A PE20150635A1 PE 20150635 A1 PE20150635 A1 PE 20150635A1 PE 2015000277 A PE2015000277 A PE 2015000277A PE 2015000277 A PE2015000277 A PE 2015000277A PE 20150635 A1 PE20150635 A1 PE 20150635A1
Authority
PE
Peru
Prior art keywords
propharmacs
aminoquinazoline
kinase inhibitor
new prodrugs
quinazolylamine
Prior art date
Application number
PE2015000277A
Other languages
English (en)
Inventor
Linda N Casillas
Pamela A Haile
Jr Robert W Marquis
Gren Wang
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50278703&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20150635(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of PE20150635A1 publication Critical patent/PE20150635A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La invencion describe compuestos que tienen la formula: en donde X es tal como se define en el documento, y metodos para prepararlos y emplearlos. Esta referida a nuevos profarmacos de una quinazolilamina que inhibe cinasa RIP2, preferiblemente nuevos profarmacos de 2-((4-(benzo[d]tiazol-5-ilamino)-6-(terc.-butilsulfonil)quinazolin-7-il)oxi)etanol.
PE2015000277A 2012-09-13 2013-09-13 Profarmacos de aminoquinazolina inhibidora de cinasa PE20150635A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261700422P 2012-09-13 2012-09-13
US201361767387P 2013-02-21 2013-02-21

Publications (1)

Publication Number Publication Date
PE20150635A1 true PE20150635A1 (es) 2015-05-24

Family

ID=50278703

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000277A PE20150635A1 (es) 2012-09-13 2013-09-13 Profarmacos de aminoquinazolina inhibidora de cinasa

Country Status (34)

Country Link
US (3) US9586953B2 (es)
EP (2) EP2895174B1 (es)
JP (1) JP6246813B2 (es)
KR (1) KR102101527B1 (es)
CN (1) CN104619327B (es)
AR (1) AR092529A1 (es)
AU (1) AU2013315396B2 (es)
BR (1) BR112015005694A2 (es)
CA (1) CA2886467C (es)
CL (1) CL2015000614A1 (es)
CR (1) CR20150132A (es)
CY (1) CY1120236T1 (es)
DK (1) DK2895174T3 (es)
DO (1) DOP2015000060A (es)
EA (1) EA028146B1 (es)
ES (1) ES2663237T3 (es)
HK (1) HK1251222A1 (es)
HR (1) HRP20180411T1 (es)
HU (1) HUE036347T2 (es)
IL (1) IL237263B (es)
LT (1) LT2895174T (es)
ME (1) ME02985B (es)
MX (1) MX371356B (es)
NZ (1) NZ628452A (es)
PE (1) PE20150635A1 (es)
PH (1) PH12015500363B1 (es)
PL (1) PL2895174T3 (es)
PT (1) PT2895174T (es)
RS (1) RS57144B1 (es)
SG (1) SG11201501139RA (es)
SI (1) SI2895174T1 (es)
SM (1) SMT201800158T1 (es)
TW (1) TWI592417B (es)
WO (1) WO2014043446A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2609578T3 (es) 2011-03-04 2017-04-21 Glaxosmithkline Intellectual Property Development Limited Amino-quinolinas como inhibidores de quinasa
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
TW201425307A (zh) 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基－喹啉類
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
JP6301374B2 (ja) 2013-02-21 2018-03-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ キナーゼ阻害剤としてのキナゾリン類
GB201506872D0 (en) * 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
NZ747259A (en) * 2016-04-04 2022-11-25 Chemocentryx Inc Soluble c5ar antagonists
KR102472736B1 (ko) 2016-09-15 2022-12-02 베링거 인겔하임 인터내셔날 게엠베하 Ripk2의 저해제로서의 헤테로아릴 카복스아미드 화합물
CN112638905A (zh) * 2018-08-28 2021-04-09 南京明德新药研发有限公司 作为rip2激酶抑制剂的喹唑啉类衍生物
WO2020094613A1 (en) 2018-11-06 2020-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Nod2 inhibitors for the treatment of hereditary periodic fevers
CN114014890A (zh) * 2021-03-12 2022-02-08 爱科诺生物医药(香港)有限公司 具有rip2激酶抑制活性的化合物，包含其的药物组合物，及其应用
WO2025078493A1 (en) * 2023-10-11 2025-04-17 Institut National de la Santé et de la Recherche Médicale Local administration of ripk2 inhibitors for the curative treatment of allergic asthma
WO2025092821A1 (zh) * 2023-11-01 2025-05-08 成都赜灵生物医药科技有限公司 喹唑啉衍生物类ripk2抑制剂及其用途

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916135A (en) 1989-05-08 1990-04-10 Hoechst Roussel Pharmaceuticals Inc. N-heteroaryl-4-quinolinamines
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6046206A (en) 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
EP0912559B1 (en) 1996-07-13 2002-11-06 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
WO1998005647A1 (en) 1996-08-01 1998-02-12 Dow Agrosciences Llc Quinolinium derivatives having fungicidal activity
IL128994A (en) 1996-09-25 2004-12-15 Zeneca Ltd History of quinoline and naphthyridine and their salts, processes for their preparation, pharmaceutical preparations containing them and their use as medicines
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
DE69905264T2 (de) 1998-10-01 2003-12-11 Astrazeneca Ab, Soedertaelje Chinolin- und chinazolin derivate und ihre verwendung als inhibitoren von krankheiten, bei denen cytokine beteiligt wird
GB2345486A (en) 1999-01-11 2000-07-12 Glaxo Group Ltd Heteroaromatic protein tyrosine kinase inhibitors
IL148576A0 (en) 1999-09-21 2002-09-12 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
WO2001055116A2 (en) 2000-01-28 2001-08-02 Astrazeneca Ab Quinoline derivatives and their use as aurora 2 kinase inhibitors
AU2001237041B9 (en) 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
US6589758B1 (en) 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
EP1313726A1 (en) 2000-08-09 2003-05-28 AstraZeneca AB Quinoline derivatives having vegf inhibiting activity
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
GB0104422D0 (en) 2001-02-22 2001-04-11 Glaxo Group Ltd Quinoline derivative
CA2441501C (en) 2001-03-23 2010-09-14 Bayer Corporation Rho-kinase inhibitors
WO2002076976A2 (en) 2001-03-23 2002-10-03 Bayer Corporation Rho-kinase inhibitors
SE0101675D0 (sv) 2001-05-11 2001-05-11 Astrazeneca Ab Novel composition
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
WO2003026666A1 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors
US7402585B2 (en) 2001-12-24 2008-07-22 Astrazeneca Ab Substituted quinazoline derivatives as inhibitors of aurora kinases
US7645878B2 (en) 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
AU2003286711A1 (en) 2002-10-25 2004-05-13 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
US20040122161A1 (en) 2002-12-21 2004-06-24 Paul Charles W. Hot melt adhesive based on acrylic block copolymers
SI1578755T1 (sl) 2002-12-24 2007-12-31 Astrazeneca Ab Fosfonooksi kinazolinski derivati in njihova farmacevtska uporaba
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
EP1636195A1 (en) 2003-05-27 2006-03-22 Pfizer Products Inc. Quinazolines and pyrido[3,4-d]pyrimidines as receptor tyrosine kinase inhibitors
KR101218213B1 (ko) 2003-07-03 2013-01-04 시토비아 인크. 카스파제의 활성인자 및 세포자멸사의 유도인자로서의4-아릴아미노-퀴나졸린
ATE395346T1 (de) 2003-09-16 2008-05-15 Astrazeneca Ab Chinazolinderivate als tyrosinkinaseinhibitoren
GB0321620D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
PT2213661E (pt) 2003-09-26 2011-12-15 Exelixis Inc Moduladores de c-met e métodos de uso
GEP20084572B (en) 2003-12-23 2008-12-25 Pfizer Novel quinoline derivatives
JPWO2005090332A1 (ja) 2004-03-23 2008-01-31 萬有製薬株式会社 置換キナゾリン又はピリドピリミジン誘導体
US20070299092A1 (en) 2004-05-20 2007-12-27 Wyeth Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors
US7531570B2 (en) 2004-05-27 2009-05-12 Vertex Pharmaceuticals Incorporated Treatment of diseases using ICE inhibitors
AU2005251735A1 (en) 2004-06-04 2005-12-22 Amphora Discovery Corporation Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
FR2873695A1 (fr) 2004-07-30 2006-02-03 Palumed Sa Molecules hybrides qa ou q est une aminoquinoleine et a est un antibiotique ou un inhibiteur de resistance), leur synthese et leurs utilisations en tant qu'agent antibacterien
ES2334453T3 (es) 2004-12-22 2010-03-10 Bayer Schering Pharma Aktiengesellschaft Derivado de quinolina, su utilizacion, su preparacion y medicamentos que contienen a este.
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
EP1874759A4 (en) 2005-04-06 2009-07-15 Exelixis Inc C-MET MODULATORS MODULATORS AND METHODS OF USE
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
EP1746096A1 (en) 2005-07-15 2007-01-24 4Sc Ag 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer
ITMI20052008A1 (it) 2005-10-21 2007-04-22 Ctg Pharma S R L Nuovi antimalarici derivati della 4-aminochinolina
FR2902100A1 (fr) 2006-06-13 2007-12-14 Sanofi Aventis Sa Molecules duales contenant un derive peroxydique, leur synthese et leurs applications en therapeutique
US7511063B2 (en) 2006-08-16 2009-03-31 Schering Corporation High affinity quinoline-based kinase ligands
JP2008063278A (ja) 2006-09-07 2008-03-21 Fujifilm Finechemicals Co Ltd １−ピリジン−４−イル−インドール類の製造方法
CA2662587C (en) 2006-09-11 2013-08-06 Curis, Inc. Quinazoline based egfr inhibitors
SG174772A1 (en) 2006-09-11 2011-10-28 Curis Inc Multi-functional small molecules as anti-proliferative agents
US8604044B2 (en) 2006-09-11 2013-12-10 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
TW200829555A (en) 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds
US8148532B2 (en) 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
US20080234267A1 (en) 2007-03-20 2008-09-25 Karen Elizabeth Lackey Compounds and Methods of Treatment
WO2008119771A2 (en) 2007-03-30 2008-10-09 Clanotech Ab Quinoline-s-carboxylic acid derivatives as tyrosine kinase inhibitors
JP5309131B2 (ja) 2007-04-23 2013-10-09 サノフイ Ｐ２ｙ１２アンタゴニストとしてのキノリン−カルボキサミド誘導体
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
CL2008001577A1 (es) 2007-06-01 2008-07-25 Wyeth Corp Metodo para tratar una leucemia positiva en un sujeto resistente a imatinib que comprende el uso de un compuesto derivado de 3-ciano-quinolina.
CN101362719B (zh) 2007-08-06 2012-04-18 北京师范大学 喹啉类衍生物以及包含其的组合物
US7790746B2 (en) 2007-10-12 2010-09-07 Supergen, Inc. Quinoline derivatives for modulating DNA methylation
US7939546B2 (en) 2007-10-12 2011-05-10 Supergen, Inc. Quinoline derivatives for modulating DNA methylation
EP2072502A1 (de) 2007-12-20 2009-06-24 Bayer Schering Pharma Aktiengesellschaft Sulfoximid-substituierte Chinolin- und Chinazolinderivate als Kinase-Inhibitoren
GB0801416D0 (en) 2008-01-25 2008-03-05 Piramed Ltd Pharmaceutical compounds
MX2010009669A (es) 2008-03-06 2010-09-22 Genentech Inc Terapia de combinacion con antagonistas de c-met y egfr.
TW201022214A (en) 2008-10-17 2010-06-16 Genentech Inc Treatment method
DE102008062566A1 (de) * 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Aminosäureester-Prodrugs und ihre Verwendung
PH12012500097A1 (en) 2009-07-21 2011-01-27 Shanghai Inst Organic Chem Potent small molecule inhibitors of autophagy, and methods of use thereof
WO2011112588A2 (en) * 2010-03-08 2011-09-15 Case Western Reserve University Compositions and methods for treating inflammatory disorders
WO2011120025A1 (en) 2010-03-26 2011-09-29 Glaxo Group Limited Indazolyl-pyrimidines as kinase inhibitors
JP2013523658A (ja) 2010-03-26 2013-06-17 グラクソ グループ リミテッド キナーゼ阻害剤としてのピラゾリル‐ピリミジン
EP2552208A4 (en) 2010-03-31 2014-07-09 Glaxo Group Ltd IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS
US20130053375A1 (en) 2010-05-07 2013-02-28 Glaxo Group Limited Amino-quinolines as kinase inhibitors
UY33549A (es) 2010-08-10 2012-01-31 Glaxo Group Ltd Quinolil aminas como agentes inhibidores de las quinasas
WO2012027495A1 (en) 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
BR112013014708B1 (pt) 2011-02-28 2021-10-19 Sunshine Lake Pharma Co., Ltd. Composto, composição farmacêutica, e, uso de um composto ou composição farmacêutica
ES2609578T3 (es) 2011-03-04 2017-04-21 Glaxosmithkline Intellectual Property Development Limited Amino-quinolinas como inhibidores de quinasa
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
TW201425307A (zh) 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基－喹啉類
JP6301374B2 (ja) 2013-02-21 2018-03-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ キナーゼ阻害剤としてのキナゾリン類

Also Published As

Publication number Publication date
CY1120236T1 (el) 2019-07-10
CA2886467C (en) 2020-07-21
MX371356B (es) 2020-01-27
IL237263B (en) 2018-10-31
EA201590561A1 (ru) 2015-06-30
EP2895174B1 (en) 2018-01-10
AR092529A1 (es) 2015-04-22
KR102101527B1 (ko) 2020-04-16
AU2013315396B2 (en) 2016-09-08
ME02985B (me) 2018-10-20
HRP20180411T1 (hr) 2018-04-20
PH12015500363A1 (en) 2015-04-20
SMT201800158T1 (it) 2018-05-02
PL2895174T3 (pl) 2018-06-29
EP3323819A1 (en) 2018-05-23
TWI592417B (zh) 2017-07-21
CN104619327B (zh) 2017-03-08
SG11201501139RA (en) 2015-04-29
MX2015003276A (es) 2015-07-06
LT2895174T (lt) 2018-04-10
EP2895174A1 (en) 2015-07-22
US9695161B2 (en) 2017-07-04
HUE036347T2 (hu) 2018-07-30
JP2015529681A (ja) 2015-10-08
WO2014043446A1 (en) 2014-03-20
SI2895174T1 (en) 2018-04-30
PH12015500363B1 (en) 2015-04-20
RS57144B1 (sr) 2018-07-31
HK1251222A1 (en) 2019-01-25
IL237263A0 (en) 2015-04-30
KR20150053919A (ko) 2015-05-19
CL2015000614A1 (es) 2015-08-28
AU2013315396A1 (en) 2015-03-05
CA2886467A1 (en) 2014-03-20
ES2663237T3 (es) 2018-04-11
DK2895174T3 (en) 2018-02-26
CR20150132A (es) 2015-05-04
NZ628452A (en) 2016-08-26
BR112015005694A2 (pt) 2017-07-04
PT2895174T (pt) 2018-03-15
US20160207913A1 (en) 2016-07-21
TW201414744A (zh) 2014-04-16
EA028146B1 (ru) 2017-10-31
US20150045323A1 (en) 2015-02-12
US20170258794A1 (en) 2017-09-14
EP3323819B1 (en) 2020-02-26
DOP2015000060A (es) 2015-05-15
US9586953B2 (en) 2017-03-07
EP2895174A4 (en) 2016-03-30
JP6246813B2 (ja) 2017-12-13
CN104619327A (zh) 2015-05-13
HK1212223A1 (en) 2016-06-10

Similar Documents

Publication Publication Date Title
PE20150635A1 (es) Profarmacos de aminoquinazolina inhibidora de cinasa
AR132854A2 (es) Compuestos e intermedios que inhiben mdm2 y procesos para fabricar los mismos
AR117113A2 (es) Inhibidor de la quinasa que regula la señal de la apoptosis
CO6842020A2 (es) Inhibidores de la tirosina-quinasa de bruton
CR20140519A (es) Derivados de benzamida para la inhibición de la actividad de abl 1, abl 2 y bcr-abl 1
CR11793A (es) 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas
PE20150666A1 (es) Inhibidores de serina/treonina cinasa
CR20200276A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamientos de la hepatitis b (divisional exp. 2015-0059)
CO6831982A2 (es) Pirazolo[4,3-d]pirimidinas útiles como inhibidores de cinasas
EP2854859A4 (en) CRYSTALLINE FORMS OF A BRUTON TYROSINE KINASE HEATHER
CR11757A (es) Compuestos de triazina como inhibidores mtor y quinasa pi3
UY32585A (es) Nuevos derivados del indazol utiles como inhibidores de la familia fosfoinositida 3´oh quinasa
CR20130470A (es) INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO [2,3-d]PIRIMIDINA TROMPOMIOSINA
CR20120397A (es) Inhibidores del virus de la hepatitis c
GT201400178A (es) Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks
UY32096A (es) Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones
CO6852067A2 (es) Derivados de 1 -oxo- 1h - ftalazin-2 -ilo comoinhibidores de la tirosina-quinasa de bruton
MX341446B (es) Compuestos heterociclicos fusionados como inhibidores de fosfodiesterasas (pdes).
BR112014005226A2 (pt) derivados de benzonitrila como inibidores de cinase
PE20140065A1 (es) Sal(es) de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]-pirimidin-6-carboxilico y procesos para su elaboracion
CR20130233A (es) Derivados que quinazolin-4 (3h)-ona utilizados como inhibidores de pi3 cinaza
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
CR20150061A (es) Compuesto de pirazolopirimidinas
EP2685992A4 (en) AMINOCHINOLINE AS A KINASEHEMMER
UY32747A (es) 2-carboxamida-cicloamino-ureas sustituidas

Legal Events

Date Code Title Description
FG Grant, registration